STAT3 and cancer: Two different antagonists were employed in these studies: the small molecule WP1066 that has been shown to inhibit JAK2/STAT3 signaling and degrade total JAK2 [39] and Ruxolitinib (Ruxo), currently in use as a cancer therapeutic, which acts on JAK1 and JAK2 by forming two hydrogen bonds with the hinge region of the JAK protein (the segment that connects the N-lobe to the C-lobe of the kinase domain) and reduces phosphorylation of the JAK2 protein at Tyr1007/1008 [33].